Six Questions For TB Alliance CEO On Pretomanid And Pricing Issues
TB Alliance CEO Mel Spigelman outlines to Scrip the contours of the non-profit’s commercialization deal with Mylan for pretomanid, which is part of an oral combination regimen, and maintains that the $1/day pricing ask for the drug is based on flawed assumptions and not currently feasible.
You may also be interested in...
Scrip highlights the key transactions involving Indian firms in 2019. Divestments and licensing were among the prominent themes that dotted the deal landscape in the year gone by.
US FDA's approval of the TB Alliance's pretomanid regimen for highly treatment-resistant tuberculosis comes with an LPAD designation and advisory committee-requested language to limit use.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.